vs

Side-by-side financial comparison of Perion Network Ltd. (PERI) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Perion Network Ltd. is the larger business by last-quarter revenue ($368.7M vs $207.3M, roughly 1.8× Ultragenyx Pharmaceutical Inc.). Perion Network Ltd. runs the higher net margin — 2.1% vs -62.0%, a 64.1% gap on every dollar of revenue. Perion Network Ltd. produced more free cash flow last quarter ($-2.9M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 16.4%).

Perion Network Ltd. is a publicly traded advertising technology company that provides digital advertising technology solutions to advertisers, agencies, retailers, and publishers. Its core offerings are delivered through Perion One, a unified omnichannel advertising platform designed to support campaign planning, activation, optimisation, and measurement across channels and verticals including connected television (CTV), digital out-of-home (DOOH), display, video advertising, as well as retai...

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

PERI vs RARE — Head-to-Head

Bigger by revenue
PERI
PERI
1.8× larger
PERI
$368.7M
$207.3M
RARE
Higher net margin
PERI
PERI
64.1% more per $
PERI
2.1%
-62.0%
RARE
More free cash flow
PERI
PERI
$97.9M more FCF
PERI
$-2.9M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
16.4%
PERI

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
PERI
PERI
RARE
RARE
Revenue
$368.7M
$207.3M
Net Profit
$7.7M
$-128.6M
Gross Margin
Operating Margin
2.0%
-54.7%
Net Margin
2.1%
-62.0%
Revenue YoY
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PERI
PERI
RARE
RARE
Q4 25
$207.3M
Q3 25
$368.7M
$159.9M
Q2 25
$266.5M
$166.5M
Q1 25
$157.8M
$139.3M
Q4 24
$164.6M
Q3 24
$508.9M
$139.5M
Q2 24
$323.6M
$147.0M
Q1 24
$145.2M
$108.8M
Net Profit
PERI
PERI
RARE
RARE
Q4 25
$-128.6M
Q3 25
$7.7M
$-180.4M
Q2 25
$5.6M
$-115.0M
Q1 25
$11.8M
$-151.1M
Q4 24
$-133.2M
Q3 24
$78.0M
$-133.5M
Q2 24
$45.2M
$-131.6M
Q1 24
$23.8M
$-170.7M
Operating Margin
PERI
PERI
RARE
RARE
Q4 25
-54.7%
Q3 25
2.0%
-106.9%
Q2 25
-1.7%
-64.8%
Q1 25
5.4%
-102.6%
Q4 24
-74.3%
Q3 24
15.1%
-94.6%
Q2 24
13.7%
-79.1%
Q1 24
16.9%
-151.9%
Net Margin
PERI
PERI
RARE
RARE
Q4 25
-62.0%
Q3 25
2.1%
-112.8%
Q2 25
2.1%
-69.0%
Q1 25
7.5%
-108.5%
Q4 24
-80.9%
Q3 24
15.3%
-95.7%
Q2 24
14.0%
-89.5%
Q1 24
16.4%
-156.8%
EPS (diluted)
PERI
PERI
RARE
RARE
Q4 25
$-1.28
Q3 25
$-1.81
Q2 25
$-1.17
Q1 25
$-1.57
Q4 24
$-1.34
Q3 24
$-1.40
Q2 24
$-1.52
Q1 24
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PERI
PERI
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$156.2M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$722.9M
$-80.0M
Total Assets
$915.5M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PERI
PERI
RARE
RARE
Q4 25
$421.0M
Q3 25
$156.2M
$202.5M
Q2 25
$156.2M
$176.3M
Q1 25
$156.2M
$127.1M
Q4 24
$174.0M
Q3 24
$187.6M
$150.6M
Q2 24
$187.6M
$480.7M
Q1 24
$187.6M
$112.3M
Stockholders' Equity
PERI
PERI
RARE
RARE
Q4 25
$-80.0M
Q3 25
$722.9M
$9.2M
Q2 25
$722.9M
$151.3M
Q1 25
$722.9M
$144.2M
Q4 24
$255.0M
Q3 24
$718.1M
$346.8M
Q2 24
$718.1M
$432.4M
Q1 24
$718.1M
$140.3M
Total Assets
PERI
PERI
RARE
RARE
Q4 25
$1.5B
Q3 25
$915.5M
$1.2B
Q2 25
$915.5M
$1.3B
Q1 25
$915.5M
$1.3B
Q4 24
$1.5B
Q3 24
$1.1B
$1.5B
Q2 24
$1.1B
$1.6B
Q1 24
$1.1B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PERI
PERI
RARE
RARE
Operating Cash FlowLast quarter
$2.6M
$-99.8M
Free Cash FlowOCF − Capex
$-2.9M
$-100.8M
FCF MarginFCF / Revenue
-0.8%
-48.6%
Capex IntensityCapex / Revenue
1.5%
0.5%
Cash ConversionOCF / Net Profit
0.34×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PERI
PERI
RARE
RARE
Q4 25
$-99.8M
Q3 25
$2.6M
$-91.4M
Q2 25
$-108.3M
Q1 25
$-166.5M
Q4 24
$-79.3M
Q3 24
$105.2M
$-67.0M
Q2 24
$-77.0M
Q1 24
$17.8M
$-190.7M
Free Cash Flow
PERI
PERI
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-2.9M
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$104.7M
$-68.6M
Q2 24
$-79.0M
Q1 24
$17.6M
$-193.9M
FCF Margin
PERI
PERI
RARE
RARE
Q4 25
-48.6%
Q3 25
-0.8%
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
20.6%
-49.2%
Q2 24
-53.7%
Q1 24
12.2%
-178.2%
Capex Intensity
PERI
PERI
RARE
RARE
Q4 25
0.5%
Q3 25
1.5%
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
0.1%
1.2%
Q2 24
1.4%
Q1 24
0.1%
3.0%
Cash Conversion
PERI
PERI
RARE
RARE
Q4 25
Q3 25
0.34×
Q2 25
Q1 25
Q4 24
Q3 24
1.35×
Q2 24
Q1 24
0.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PERI
PERI

Advertising Solutions$231.4M63%
Search Advertising$137.3M37%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons